Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The importance and imperative of immediate treatment for all people living with HIV is finally indisputable, but laws, policies, and discriminatory neglect continue to keep testing, […]
“Test and treat” is the ideal — but in TB and other illnesses, “guess and treat” is the more common reality
Science Speaks staff writer and Global Health Policy Research Coordinator Rabita Aziz attended the McGill University Summer Institute in Infectious Diseases and Global Health June 13-17. MONTREAL […]
Zika pregnancy and infant study to seek information on scope of risks from virus, strategies to meet impacts
And as summer starts in North America, legislators prepare for break . . . //Post updated June 22, 2016 with information on potential environmental factors the […]
Shaheen amendment reverses bill’s defunding of UNFPA, reinstatement of Global Gag Rule, family planning cuts While the Senate Appropriations Committee voted today to flat-fund most global health […]